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The nature and extent of the impact of gender and repro-
ductive function on mood has been the subject of specu-
lation and controversy for centuries. Over the past 50 years,
however, it has become increasingly clear that not only is
the brain a major target of reproductive steroid hormones,
but additionally, the steroid hormones, as neuroregulators,
create a context that influences a broad range of brain
activities; ie, neural actions and resultant behaviors are
markedly different in the presence and absence of gonadal
steroids. In turn, the actions of gonadal steroids are them-
selves context-dependent. Thus, even where it can be
demonstrated that gonadal steroids trigger mood disor-
ders, the triggers are normal levels of gonadal steroids (to
be contrasted with the mood disturbances accompanying
endocrinopathies), and the mood disorders appear only in
a subset of susceptible individuals. The context specificity
and differential susceptibility to affective dysregulation
seen in women with reproductive endocrine–related mood
disorders are undoubtedly important underlying charac-
teristics of a wide range of psychiatric disorders in which
the triggers have not yet been identified. Consequently,
reproductive endocrine–related mood disorders offer
unparalleled promise for the identification of those con-
textual variables that permit biological stimuli to differ-
entially translate into depression in individuals at risk.
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his issue of Dialogues in Clinical Neuroscience
focuses on depression and senescence in women for sev-
eral reasons. First, mood disorders linked to reproduc-
tive endocrine change in women (eg,premenstrual syn-
drome [PMS], postpartum depression [PPD], and
perimenopausal depression [PMD]) are clinically sig-
nificant: they are prevalent and attended to by consid-
erable morbidity. Second, it is now clear that reproduc-
tive steroids are important regulators of virtually every
aspect of brain organization and function, from neural
differentiation and migration to intracellular and inter-
cellular signaling to neuronal (and glial) survival and
death. Simply put, these steroids create a context such
that the brain functions differently in their presence and
absence.Third,political objections notwithstanding,it is
now clear that reproductive steroids play a critical role
in triggering reproductive endocrine–related mood dis-
orders, thus compromising arguments that these disor-
ders do not exist or that the ostensible link to reproduc-
tive endocrine change is illusory. Fourth, it is equally
clear that reproductive steroids do not, by themselves,
cause reproductive endocrine–related mood disorders;
ie, women with these disorders are differentially sensi-
tive to levels or changes in reproductive steroids that are
without effect on mood in women lacking these disor-
ders.
This differential sensitivity,the fact that people respond
differently to the same reproductive endocrine stimulus,
is important for three reasons. First, the failure to 
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TSelected abbreviations and acronyms
AP1 activator protein 1
AR androgen receptor
DHT dihydrotestosterone
ER estrogen receptor
fMRI functional magnetic resonance imaging
GABA γ-aminobutyric acid
hCG human chorionic gonadotropin
3α-HSOR 3α-hydroxy steroid oxidoreductase
MAPK mitogen-activated protein kinase
PET positron emission tomography
PMD perimenopausal depression
PMS premenstrual syndrome
PPD postpartum depression
T3 triiodothyronine
consider this phenomenon has been the keystone of the
argument that reproductive endocrine–related mood
disorders do not exist.The syllogism is as follows:The
effects of reproductive hormones should be similar
across individuals; not all individuals have the same
behavioral concomitants of changes in reproductive
endocrine function; therefore, reproductive hormones
have nothing to do with behavior. In other words, if
changes in reproductive steroids do not precipitate
mood disorders in everyone,they must do so in no one.
As will be shown below, this argument is fallacious and
serves to obscure rather than clarify.Second,the princi-
ple that the response to a biologic stimulus depends
upon the context in which the stimulus is administered
is generalizable and underlies much of our physiology.
Third, by understanding the means by which reproduc-
tive steroids can trigger affective change in some but not
other women,we will be in a far more powerful position
to understand the substrate underlying susceptibility to
affective disorder in general, which is better conceptu-
alized as a differential response to a stimulus rather than
as a “deficiency”state.The remainder of this paper,then,
will address the central question in reproductive psy-
chiatry/neuroscience:how is it that reproductive steroids
can trigger a depression,and why does this occur only in
some individuals?
Reproductive steroids: 
modulators of brain function
The observed links between reproductive function and
behavior date back at least several millennia toAristotle,
who noted that castration of immature male birds pre-
vented the development of characteristic male singing
and sexual behavior.
1 By the end of the 19th century,
Brown-Séquard and other “organotherapists” claimed
that the administration of ground-up extracts from ani-
mal gonads could successfully treat a variety of human
mood disorders,including depression and the anergy of
senescence.
2-5 In the 1920s and 1930s,the potential medi-
ators of these effects—the steroid hormones estradiol,
progesterone, and testosterone (and not sperm, as
Brown-Séquard believed)—were isolated and charac-
terized. Forty years later, Jensen and Jacobsen
6 demon-
strated that the actions of estradiol occurred through its
binding to an intracellular protein, the estrogen recep-
tor (ER),which was isolated and identified 4 years later.
7
The means by which steroids influenced cell function
were subsequently elaborated: after diffusing into the
cell,the steroid bound and activated its receptor,a tran-
scription factor that could then bind DNA and regulate
the transcription of mRNA,which would then be trans-
lated into proteins in the cell cytoplasm.In this fashion,
reproductive steroids were found to regulate the expres-
sion of a variety of proteins of relevance for neural func-
tion (eg, neurotransmitter synthetic and metabolic
enzymes, neuropeptides, receptors, etc). More recently,
advances in neuroscience (reviewed in the accompany-
ing article by McEwen
8) have demonstrated vastly more
complex, broad-ranging, and powerful mechanisms for
neural control by reproductive steroids,and have further
uncovered several regulatory principles that help
explain how a given steroid signal may elicit diverse
behavioral responses. One inescapable, overarching
principle is that the molecular and behavioral effects of
steroids are highly context-dependent.
Cellular context
Data overwhelmingly suggest that the cell is a context
that determines the response to a stimulus.First,steroid-
activated receptors influence transcription not as soli-
tary agents, but by forming combinations with other
intracellular proteins.
9 Some of these proteins, the 
coregulators, determine whether gene transcription is
enhanced or suppressed by the activated receptor.Other
proteins,the cointegrators,permit activated receptors to
regulate genomic expression through sites (eg,activator
protein,AP1) other than the classical DNA hormone
response elements, thus expanding the range of genes
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10 Many of these proteins are tis-
sue specific,thus helping to explain how ER modulators
(eg, tamoxifen and raloxifene) can act like agonists in
some tissues (eg,bone) and like antagonists in other tis-
sues (eg, breast).
11,12 Second, different subtypes of the
steroid receptors are either coded for on different genes
(eg, estrogen receptors alpha and beta)
13 or modified
after transcription (eg, splice variants or progesterone
receptor isoforms A and B).
14 These subtypes have dif-
ferent distribution patterns in the brain,different affini-
ties for ligands, and very different actions (including
inhibition of the actions of other subtypes).
15,16Third,the
relatively slow, “genomic” effects of reproductive
steroids have been expanded in two dimensions: time,
with a variety of rapid (seconds to minutes) “nonge-
nomic”effects observed;and targets,which now include
ion channels and second messengers. Once again, the
effect observed depends upon the type of cell examined:
estradiol activates the second messenger,mitogen-acti-
vated protein kinase (MAPK),in neurons,but decreas-
es MAPK activation in cortical glia.
17
Metabolic context
As steroid hormones are highly homologous and serve
as precursors for one another, the manner in which
steroids are metabolized can markedly change the
amplitude or nature of the steroid signal.Steroid meta-
bolic enzymes, then, can contribute to the variance in a
steroid signal in several ways.First,enzymes regulate the
activation and potency of steroid hormones,as seen,for
example, with the enzyme (5α-reductase) that converts
testosterone into dihydrotestosterone (DHT),an andro-
gen with fourfold greater affinity for the androgen
receptor (AR) and fivefold greater stability.
18 Second,
enzymes determine the receptor system that is activat-
ed,as seen,for example,in the conversion by aromatase
of testosterone (acting at the AR) to estradiol (acting at
the ER).Third,the metabolism of steroids can facilitate
or inhibit the accumulation of metabolites that may be
neurotoxic, as seen, for example, with the ability of 5α-
reductase to shunt testosterone away from the pathway
leading to accumulation of estradiol,which can function
as a neurotoxin.
19,20 Fourth, enzymes may produce
steroid metabolites that have a completely different
neuromodulatory profile from that of the parent hor-
mones, as seen, for example, with the conversion of
progesterone to the neurosteroid allopregnanolone (by
5α-reductase and 3α-hydroxy steroid oxidoreductase
[3α-HSOR]),a potent modulator of the γ-aminobutyric
acid (GABA) receptor chloride ionophore.
21 Finally,
since many of the enzymes have multiple steroid sub-
strates, the enzyme activity regulates the relative
amounts of different behaviorally active metabolites;for
example,3α-HSOR both inactivates the androgen DHT
and produces the neurosteroid allopregnanolone.
22 Not
only will different metabolic profiles activate or inhibit
different receptor systems, but the consequence of the
activation of a given steroid receptor will differ depend-
ing upon which hormones are present. Estradiol and
cortisol, for example, exert opposing effects on AP1-
modulated genes through interactions with the cointe-
grator CBP/P300.
10 A steroid hormone, then, may pro-
duce markedly different effects depending upon its
metabolism and the hormonal context in which it is act-
ing.
Developmental/temporal context
Perinatal reproductive steroids create a context that
influences (organizes) brain development and the adult
behavioral repertoire. Phoenix et al
23 and Gorski et al
24
showed that prenatal exposure of female guinea pigs or
perinatal exposure of rats to androgens resulted in
enhanced behavioral sensitivity (eg, increased sexual
and aggressive behaviors) to androgens administered
during adulthood.Thus,differences in early exposure to
reproductive steroids created the capacity in adults for
different behavioral responses to the same stimulus.The
effects of reproductive steroids are also developmental
stage–specific.Estradiol,for example,stimulates its own
receptor early in development, inhibits it during adult-
hood, and stimulates it again in the context of brain
injury.
25 Modulatory effects of reproductive steroids also
differ in old and young subjects (both animals and
humans). For example, spine density in the dentate
gyrus is modulated by estradiol in old but not young
female rats.
26
These age-dependent effects are particularly of interest
given a burgeoning literature describing the ability of
reproductive steroids to regulate cell death and survival
through effects on cell survival proteins (eg,Bcl-2,Bax),
signal transduction (eg, MAPK,Akt), amyloid precur-
sor protein metabolism, and free radical species gener-
ation.
17,27-30 Effects on survival operate at both ends of the
developmental spectrum. Early effects influence prun-
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31 and the shaping of brain circuitry. Modulation of
neural and glial survival during aging provides yet
another means by which reproductive steroids may
influence the susceptibility to neuropsychiatric illness,
given the putative role of neurodegeneration in depres-
sion
32-34 and its demonstrated role in Alzheimer’s disease.
Environmental context
The brain is a nonlinear transform system,in which the
response to a stimulus can be altered as a function of
past history or present environment. Multiple demon-
strations of this process can be found in the animal lit-
erature. For example, behavioral sensitization refers to
an amplified behavioral response (eg, aggression) to
repeated exposure to a pharmacologic stimulus.
35 Two
elements of this process are of further interest. First,
Antelman has suggested that even without repeated
administration, exposure to certain drugs may yield an
amplified response upon readministration, simply by
virtue of the passage of time.
36There is a “memory”fol-
lowing exposure that alters the response when the stim-
ulus is re-presented. Second, Post and coworkers have
demonstrated that expression of behavioral sensitization
may be context dependent, in that the exaggerated
response elicited to cocaine in the test cage will not be
manifest if,after sensitization is achieved,the cocaine is
administered in the home cage.
37 Both past experience
and environment,then,may alter subsequent response.
One of the most impressive demonstrations of experi-
ence (and development)–related alterations in context
is provided by the work of Meaney and coworkers.
These authors
38 expanded the work of Levine
39 and
showed that the separation and handling of rat pups
elicited licking and grooming behavior from mothers
that differentially and permanently determined the
nature of the offspring’s response to stressors. Meaney
and coworkers then went on to demonstrate in cross-fos-
tering studies that it was the maternal licking and
grooming behavior, not the genetic factors, that influ-
enced the licking and grooming behavior (as well as the
stress responsivity) of the female offspring,and that the
“adopted” licking and grooming behavior and stress
responsivity were passed down to subsequent genera-
tions.
40 This series of studies, then, demonstrates that
maternal behavior can alter the developmental context,
such that permanent and dramatic differences in
response—from the transcriptional to the behavioral
level—are programmed into the offspring. Several
studies also demonstrate the exquisite sensitivity of
reproductive physiology and behavior to environmen-
tal alterations during development.Ward and Weisz
41,42
demonstrated that male offspring of a rat dam stressed
during gestation were demasculinized,with lower testos-
terone levels (on critical gestational days) and deficient
adult male mating behavior.
43 Moore et al
44 observed
that the size of the sexually dimorphic spinal nucleus of
the bulbocavernosus as well as adult male mating behav-
ior were in part determined by maternal licking of the
anogenital region of the pup,which in turn appeared to
be elicited by androgens in the rat pup urine. Finally,
reproductive hormones interact with environmental fac-
tors during development to determine the adult behav-
ioral repertoire.Adult aggressive behavior in mice can
be attenuated by prepubertal castration;the attenuation,
however,is blunted to the extent to which the mouse has
already been exposed to aggressive encounters.
45 These
examples demonstrate that current and past environ-
ments and experience can create a context in which the
same hormonal or environmental stimulus may elicit
any of a range of behavioral responses.
Gender context
Early hypotheses that the brain displays sex-related dif-
ferences in structure and function were confirmed by the
demonstrations by Pfaff
46 of sexual dimorphisms in rat
brain morphology and by Raisman and Field
47 of sex-
related differences in the synaptic density of the preop-
tic area in the rat.There is now an impressive literature
detailing sexual dimorphisms at all levels of the neu-
roaxis, including differences in the following: nuclear
volume; neuron number, size, density, morphology, and
gene expression; signal transduction; neuronal neuritic
branching patterns; synapse formation; and physiologi-
cal and behavioral response.
48,49 Given the ability of
reproductive steroids to regulate virtually all stages of
brain development,from neurogenesis to neural migra-
tion, differentiation, synaptogenesis, survival, and
death,
49 the wide range of brain dimorphisms is not sur-
prising.Nonetheless,the source and significance of many
of the dimorphisms are far from clear. For example,
while exposure to reproductive steroids is believed to
organize (perinatally) or activate (adulthood) most
dimorphisms, Reisert and Pilgrim
50 showed that dimor-
phisms in the course of development of embryonic mes-
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genetic control (ie,they are determined well before the
appearance of any differences in reproductive steroid
levels). Similarly, both the morphologic (eg, neuritic
extension) and functional (eg, signal transduction)
responses of cultured neurons and glia to reproductive
steroids have been shown to display dramatic sexual
dimorphisms despite exposure to identical levels of
steroid,
17,51,52 ie,the dimorphic response cannot be attrib-
uted to differences in the steroid milieu of males and
females. Additionally, the existence of brain sexual
dimorphisms often is not translatable into gender-relat-
ed differences in behavior.
53,54 Still, the widespread
dimorphisms in animals (as well as the demonstrations
of sexual dimorphisms in brain structure and physiolo-
gy in humans)
55 provide a basis for inferring the mech-
anisms underlying reported gender dimorphisms in
depression and other psychiatric disorders,ie,differences
in prevalence,phenomenology (including characteristic
symptoms,age of onset,susceptibility to recurrence,and
stress responsivity), and treatment response character-
istics.
Sexual dimorphisms
Sexual dimorphisms in depression
Depression differs in women and men in a number of
respects. Studies consistently demonstrate a twofold
increased prevalence of depression in women compared
with men,
56-59 and this increased prevalence has been
observed in a variety of countries.
58 A two- to threefold
increased prevalence of dysthymia and threefold
increase in seasonal affective disorder in women has also
been noted,
60, 61 while bipolar illness is equiprevalent in
men and women
56,62,63 (reviewed in reference 64).
Prepubertal depression prevalence rates are not higher
in girls,
65,66 possibly reflecting ascertainment bias (depres-
sed boys may be more likely to come to the attention of
health care providers) or the possibility that prepuber-
tal major depression is premonitory of bipolar illness.
67
With some exceptions,the age of onset
58,59,68-71 (but also see
references 72 to 75),type of symptoms,severity,and like-
lihood of chronicity and recurrence
58,59,68,72,76-78 (but also see
references 79 to 83) display few differences between men
and women.Women are more likely to present with anx-
iety,atypical symptoms,or somatic symptoms
60,68,72,81,83,85 are
more likely to report symptoms (particularly in self-
ratings),
60,68,85 are more likely to report antecedent stress-
ful events,
86,87 and manifest a more robust effect of stress
on the likelihood of developing depression during ado-
lescence.
88Women also display increased comorbidity of
anxiety and eating disorders,
73,89-91 thyroid disease,
92,93 and
migraine headaches,
94 as well as lower lifetime preva-
lence of substance abuse and dependence.
72,73 Reported
differences in treatment response characteristics in
women compared with men include poor response to 
tricyclics
95-98 particularly in younger women,
96 superior
response to selective serotonin reuptake inhibitors
(SSRIs) or monoamine oxidase inhibitors (MAOIs),
99,100
and a greater likelihood of response to triiodothyronine
(T3) augmentation.
93 The extent to which these differ-
ences reflect gender-related differences in pharmaco-
kinetics
101-107 remains to be determined.Finally,while the
prevalence of bipolar disorder is comparable in men and
women, women are more likely to develop rapid
cycling
64 and may be more susceptible to antidepressant-
induced rapid cycling.
108
It is one matter to identify sex-related differences in
depression and quite another to interpret their meaning.
Specifically, one cannot infer that the observed differ-
ences are a product or a reflection of sex-specific biol-
ogy.Sex-related differences in the prevalence of depres-
sion, for example, could occur consequent to increased
number and severity of stressors experienced by women
(eg, greater demands to manage both home and voca-
tional responsibilities; societal encouragement of con-
ciliatory behavior and discouragement of expression of
anger;a lack of social empowerment) or to social stigma-
tization of endorsement of depressive symptoms in men.
Nonetheless,the potential for sex-dependent biology to
play a significant role in affective and cognitive disorders
is suggested by the following (described below):(i) sex-
ual dimorphisms in brain structure and physiology have
been identified in humans;(ii) reproductive steroids reg-
ulate brain function in humans in vivo; and (iii) repro-
ductive steroids play a role in the precipitation and treat-
ment of mood disorders that are linked to periods of
reproductive endocrine change.
Brain sexual dimorphisms in humans
While a biological basis for sex-dependent differences
in the susceptibility to or expression of depression has
not been demonstrated,structural and functional imag-
ing studies have identified a variety of sex-differences in
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organization of the brain,with brain activation response
to rhyming task lateralized in men but not women
109;(ii)
gender-specific decreases in regional brain volume (cau-
date in men and globus pallidus, putamen in women)
during development
110; (iii) increased neuronal density
in the temporal cortex in women
31; (iv) greater inter-
hemispheric coordinated activation of brain regions in
women
111; (v) larger volume hypothalamic nucleus
(interstitial nucleus of the anterior hypthalamus–3
[INAH–3]) in men
112; (vi) differences in both resting
blood flow and the activation pattern accompanying
self-induced mood change
113; (vii) decreased serotonin
receptor 5-HT2 binding in the frontal, parietal, tempo-
ral,and cingulate cortices in women
114;(viii) differences
in whole brain serotonin synthesis (interpreted as
decreased in women but possibly increased if correct-
ed for plasma free tryptophan levels
115); (ix) higher and
more symmetric cerebral blood flow in women
116-120; (x)
greater asymmetry in the planum temporale in men
121;
and (xi) greater brain glucose metabolism (19%) in
women.
122,123 Data from several studies employing simi-
lar technologies suggest that reproductive steroids may
mediate some of the observed dimorphisms.
Regulation of brain physiology by reproductive steroids
Berman et al
124 demonstrated that the normal pattern of
cognitive task–activated cerebral blood flow was elimi-
nated by induced hypogonadism and restored by
replacement with estradiol or progesterone, findings
supported by Shaywitz et al,
125 who demonstrated estro-
gen enhancement of cognitive task–stimulated brain
regional activation (functional magnetic resonance
imaging [fMRI]) in postmenopausal women.Wong et
al
126 demonstrated in a small number of subjects that
dopamine receptor density in the caudate (measured by
positron emission tomography [PET]) varied as a func-
tion of the menstrual cycle (lower in the follicular
phase).Further,in two recent studies using paired-pulse
transcranial magnetic stimulation,Smith et al
127,128 showed
that cortical facilitation was enhanced in the late follic-
ular phase, while cortical inhibition was enhanced dur-
ing the luteal phase,consistent with putative central exci-
tatory effects of estradiol and inhibitory effects of
progesterone metabolites.
Despite gender-related and reproductive steroid–relat-
ed differences in brain physiology,it is the investigation
of mood disorders linked to reproductive endocrine
change that offers the greatest potential insight into the
role of reproductive steroids in the regulation and dys-
regulation of affect.
Reproductive endocrine–related 
mood disorders
Premenstrual syndrome
While Frank is credited with the first description of “pre-
menstrual tension”in 1931,reports of mood and behav-
ioral disturbances confined to the luteal phase of the
menstrual cycle appeared earlier in the medical litera-
ture of the 19th century.For example,in 1847,Dr Ernst
G.Von Feuchtersleben stated that “the menses in sensi-
tive women is almost always attended by mental uneasi-
ness,irritability or sadness.”
129As the symptoms of PMS
occurred in a menstrual cycle phase–specific fashion (ie,
only in the luteal phase), it was presumed that abnor-
malities in the hormonal constituents of the menstrual
cycle (eg, estradiol, progesterone) must underlie PMS.
Despite the appeal of this hormone excess or deficiency
hypothesis, however, early studies of the putative hor-
monal etiologies of PMS were inconsistent in their con-
clusions.A major source of study inconsistency was iden-
tified in the 1980s,
130 namely that samples of women with
PMS were selected (diagnosed) with highly unreliable
techniques (ie, unconfirmed history).Without prospec-
tive demonstration of luteal phase–restricted symptom
expression, samples selected were certain to contain a
large number of false positives, thus rendering the data
obtained ungeneralizable to the population with PMS.
131
This requirement for prospective confirmation of luteal
phase symptomatology was ultimately incorporated into
diagnostic criteria for PMS
132 and late luteal phase dys-
phoric disorder (LLPDD)/premenstrual dysphoric dis-
order (PMDD).
133 While the use of these diagnostic cri-
teria/guidelines has permitted greater homogeneity of
samples across studies—a requirement for comparison
and generalization of results obtained—data subse-
quently generated have provided little if any evidence
for hormonal excess or deficiency as etiologically rele-
vant in PMS. Indeed, more recent studies have, if any-
thing,largely preserved the formerly observed inconsis-
tency. For example, Wang et al
134 observed increased
estradiol and decreased progesterone levels in women
with PMS,Redei and Freeman
135 reported nonsignificant
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Facchinetti et al
136 found no differences from controls in
integrated progesterone levels. Results from studies of
androgen levels have been similarly inconsistent,
demonstrating both normal and decreased testosterone
levels
137-139 and elevated and decreased free testosterone
levels.
138,139 In conclusion, there is no consistent or con-
vincing evidence that PMS is characterized by abnormal
circulating plasma levels of gonadal steroids or
gonadotropins or by hypothalamic-pituitary-ovarian axis
dysfunction. Several studies do, however, suggest that
levels of estradiol, progesterone, or neurosteroids (eg,
pregnenolone sulfate) may be correlated with symptom
severity in women with PMS.
134,140,141 (See references 142
and 143 for summaries of hormonal studies of PMS.)
If PMS is not due to a deficiency or excess of reproduc-
tive steroids (or of any other hormone studied to date),
do these steroids play any role at all in the precipitation
of the syndrome? We attempted to answer this question
by posing four questions.
Is the luteal phase necessary for the appearance of
PMS?
If there was no obvious abnormality in the activity of the
reproductive axis, was PMS in fact dependent on the
menstrual cycle for its expression,or could it be dissoci-
ated from the luteal phase? We blinded women to their
position in the menstrual cycle by administering the
progesterone receptor antagonist RU-486 (which both
precipitates menses and ends corpus luteum activity),
alone or with human chorionic gonadotropin (hCG)
(which preserves corpus luteum activity).
144 Thus, after
receiving the RU-486 (6 days after the LH surge), sub-
jects did not know whether they were in the follicular
phase of the next cycle (RU-486 alone) or in the pre-
served luteal phase of the initial cycle (RU-486 + hCG).
Subjects in all three groups (a placebo-only group was
included) experienced highly comparable symptoms that
were significantly greater than those seen in the follicu-
lar phase;ie,women receiving RU-486 alone developed
characteristic symptoms of PMS in the experimentally
produced follicular phase of the next cycle.PMS,there-
fore, was not dependent on reproductive endocrine
changes occurring in the mid-late luteal phase, as we
were able to eliminate those changes without influenc-
ing subsequent symptom development.This left open
the question of whether events occurring earlier than the
mid-late luteal phase might,nonetheless,be influencing
subsequent symptom development.
If you suppress ovarian activity, can you prevent the
symptoms of PMS?
As the RU-486 study eliminated only the mid-late luteal
phase,PMS symptoms might have appeared consequent
to reproductive endocrine events occurring earlier in the
menstrual cycle.To test this possibility, we performed
“medical oophorectomies” by administering the
gonadotropin-releasing hormone (GnRH) agonist
leuprolide acetate (3.75 mg) in a placebo-controlled par-
allel-design study in 20 women with PMS. Leuprolide
but not placebo was highly effective in eliminating both
symptom severity and cyclicity (10/18 women respond-
ed to leuprolide and 0/10 responded to placebo).
145This
confirmed similar observations by Bancroft et al
146 and
Mortola et al,
147 and suggested that PMS was indeed
dependent upon ovarian steroid production.
In those in whom ovarian suppression effectively pre-
vents the expression of PMS, will exogenous adminis-
tration of gonadal steroids (either estrogen or proges-
terone) precipitate the return of characteristic
symptoms?
Eighteen women whose PMS symptoms were signifi-
cantly attenuated or eliminated by leuprolide-induced
ovarian suppression were then continued on leuprolide
and received in addition (in a double-blind, crossover
fashion) estradiol (4 weeks followed by a fifth week in
combination with progesterone to promote endometri-
al shedding) and progesterone (4 weeks). Five of these
women received an additional 1 month of placebo
“addback”in order to control for patients’ expectations,
specifically the recognition that they were taking some-
thing new. Finally, the same regimen of leuprolide-
induced hypogonadism followed by sequential hormone
replacement was performed in 15 control women, in
whom the absence of menstrual cycle–related mood dis-
turbances was confirmed with longitudinal ratings prior
to study entry.The women with PMS whose symptoms
were successfully eliminated (or attenuated) by leupro-
lide-induced hypogonadism experienced significant
return of symptoms on either estradiol or progesterone,
but not on placebo. Characteristically, symptoms
returned within 2 weeks of initiating hormone replace-
Gonadal steroids,brain,and behavior - Rubinow and Schmidt Dialogues in Clinical Neuroscience - Vol 4 . No.2 . 2002
129ment and remitted by the fourth week of administration.
In the control women lacking a history of PMS,howev-
er, neither the hypogonadal nor the hormone replace-
ment conditions were associated with any perturbation
of mood.
145 Consistent with the findings from our basal
hormone studies,
148 it appeared that PMS represents an
abnormal response to normal hormone changes or lev-
els rather than a “normal” response to a hormonal
abnormality.This study,then,raised a fundamental ques-
tion: Why do similar changes in or levels of gonadal
steroids trigger mood deterioration in women with PMS,
while showing no apparent effect on mood in women
lacking this history?
What are the potential mechanisms underlying the
increased vulnerability to gonadal steroid–triggered
mood changes in women with PMS?
While mood disorders may be seen in association with
the pathological function of certain endocrine organs
(eg, adrenal, thyroid), mood disturbances precipitated
by gonadal steroids in PMS appear in the context of nor-
mal ovarian function.There are several possible means
by which otherwise normal steroid signals might elicit a
change in behavioral state.
Altered set points for relevant neural systems (ie,a means
of conferring vulnerability)
The serotonin systems are appealing candidates for con-
ferring vulnerability to gonadal steroid–precipitated
mood changes
149:gonadal steroids and serotonin display
numerous reciprocal regulatory effects in the central
nervous system (CNS); aggression against intruders by
female rats (resident intruder model) varies with the
estrous cycle, is ovarian steroid dependent, and is pre-
vented by serotonin agonist antidepressants
150;serotonin
has a role in behaviors (eg, appetite, impulsivity, mood,
sleep, and sexual interest) that vary with the menstrual
cycle in PMS; blunted endocrine responses to seroton-
ergic agonists (eg, L-tryptophan, meta-chlorophenyl-
piperazine) have been described in PMS (although not
confined to the luteal phase)
151,152; serotonergic agonists
are efficacious in the treatment of PMS,
153 and the ther-
apeutic efficacy of serotonin agonists can be reversed by
tryptophan depletion
154 or serotonin receptor block-
ade.
155While alterations in serotonin function are clear-
ly relevant to the successful treatment of PMS symp-
toms,it remains unclear whether alterations in serotonin
function underlie the predisposition to experience PMS.
Future studies will await the development of receptor
subtype specific agonists/antagonists and access to sub-
type-specific imaging ligands.
Polymorphisms in gonadal steroid signaling pathway pro-
teins or in systems regulated by gonadal steroids
PMS offers an ideal opportunity to identify genetic con-
tributions to the vulnerability for affective disturbance,
since the offending stimuli (steroid triggers) are known.
Several polymorphisms in gonadal steroid receptors
have been shown to alter receptor transcriptional effica-
cy (eg,CAG repeat in exon 1 of the androgen receptor;
progins insertion in intron 7 of the progesterone recep-
tor) and to be associated with differential illness risk (ie,
prostate cancer or breast cancer).
156-159Additionally,the
susceptibility to the disruptive effects of estradiol on
reproductive development differs enormously (up to
100-fold) between mouse strains,with the genotype con-
tributing more to the variance than the dose of estradiol
employed.
160There is precedent,then,for inferring that
polymorphisms in the gonadal steroid–signaling pathway
or in gonadal steroid–regulated genes may alter the
nature or strength of the steroid signal as well as pheno-
type.In genetic studies that we have performed to date
in 125 women with PMS and 280 controls (C.Roca and
B. Harlow, unpublished data), no differences were
observed in the frequencies of the following polymor-
phisms:PvuII,XbaI,and TA repeat (estrogen receptor
α);CAG repeat (androgen receptor);progins,CA repeat
(progesterone receptor);T102C,His-Tyr (serotonin 2A
receptor);Cys-Ser (serotonin 2C receptor).A significant
difference has been identified,however,for the SLC6A4
promoter polymorphism of the serotonin transporter,
with a higher frequency of the L (long) allele (associat-
ed with increased transport and increased response to
SSRIs)
161,162 in the women with PMS (C. Roca et al,
unpublished data).This difference appears to reflect a
lower than predicted frequency in the controls as well as
a higher frequency in patients, suggesting that women
with documented absence of any menstrual cycle–relat-
ed mood symptoms (approximately 10% of the Harlow
sample) may be protected from the development of
symptoms and hence may be at least as informative as
illness probands in providing clues to the genetic deter-
minants of susceptibility.
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The neurosteroid metabolites of progesterone (and andro-
gens) are of considerable interest as possible mediators of
the behavioral effects of gonadal steroids. Supportive
observations are as follows: (i) the ring A–reduced
metabolites of progesterone,allopregnanolone and preg-
nanolone,are allosteric modulators of the GABAA recep-
tor/chloride ionophore
21;(ii) withdrawal of progesterone
in rats produces anxiety and insensitivity to benzodi-
azepines due to withdrawal of allopregnanolone,with con-
sequent induction of GABAA alpha-4 subunit levels and
inhibition of GABA currents
163,164;(iii) decreased plasma
allopregnanolone levels are seen in major depressive dis-
order and in depression associated with alcohol with-
drawal,with an increase in levels seen in plasma and cere-
brospinal fluid (CSF) following successful antidepressant
treatment
165-167;(iv) allopregnanolone displays anxiolytic
effects in several animal anxiety models
168 and may be
involved in the stress response
169;(v) antidepressants may
promote the reductive activity of one of the neurosteroid
synthetic enzymes (3α-HSOR),thus favoring the forma-
tion of allopregnanolone.
170While we previously reported
no differences in luteal phase allopregnanolone and preg-
nanolone levels in women with PMS compared with con-
trols,
171 in an experimental model of postpartum depres-
sion (PPD), we observed a highly significant inverse
correlation (r=0.92) between the change in allopreg-
nanolone levels from weeks 6 to 8 of hormone addback
and Beck depression ratings at week 8 of addback (see
below).
172This correlation reflected the high depression
ratings in those women with a past history of PPD,whose
allopregnanolone levels dropped or failed to increase dur-
ing the last 2 weeks of high dose addback.These findings
suggest that differences in the activity of the synthetic (or
metabolic) enzymes for neurosteroids may translate into
phenotypic differences.
At present,we do not understand the basis for the differ-
ential sensitivity seen in women with PMS:what permits
levels or changes in reproductive steroids that are without
effect on mood in women without a history of PMS to
destabilize mood in those with a history of PMS?
Nonetheless,the simultaneous requirement for a trigger
(reproductive steroids ) and an underlying vulnerability to
mood state destabilization in PMS provides a model for
thinking about affective disorders in general as well as
other mood disorders (eg,postpartum depression) specif-
ically linked to periods of reproductive endocrine change.
Postpartum depression
A reproductive endocrine–related mood disorder that is
phenomenologically similar to major depression is PPD,
the most prominent symptoms of which are sleep dis-
turbance, excessive fatigue, sadness and anhedonia,
excessive guilt or self blame, psychomotor disturbance,
and suicidal ideation.
173-175 It does not appear that there
is anything phenomenologically unique about the
depression that occurs postpartum;rather,once again,it
is the timing of the syndrome that makes it distinctive,
in this case following delivery.
However,variability in the definition of the interval dur-
ing which PPD can develop (2 weeks to 3 months post-
partum) in part accounts for the variable estimates of
the incidence and prevalence of PPD. Prevalence rates
for PPD vary between 8.3% and 14.9%.
176-181 While an
increased prevalence of depression postpartum has not
been clearly demonstrated (due, in part, again to vary-
ing intervals examined and a paucity of adequate con-
trol groups), it does appear that the relative risk of
depression increases during the first few months post-
partum.
178,182-184
While a variety of factors have been associated with the
development of PPD, including personal or family his-
tory of psychiatric illness, marital disharmony, lack of
confiding relationships,and number of life events in the
previous year,
185-187 two are of particular interest. First,
while some but not all studies show a prior history of
affective illness as a risk factor for subsequent PPD,
188-191
women with PPD as their first depressive episode
appear both less likely to experience a nonpuerperal
depression and more likely to experience a subsequent
PPD than women with nonpuerperal episodes.
192 Second,
recent studies suggest that depressive symptoms during
pregnancy may be associated with the development of
PPD.
184,189-191,193-195Any hypothetical role of reproductive
steroids in PPD must account for the increase in depres-
sive symptoms during pregnancy.
Studies have examined the relationship between PPD
and reproductive steroids by measuring steroid levels
(particularly estradiol and progesterone) or changes in
levels during pregnancy and the postpartum.The results
of these studies in general fail to show any consistent dif-
ferences between women with PPD and controls.
196
Similarly, while thyroid dysfunction may contribute to
postpartum mood dysregulation in a small group of
women, it does not appear relevant for the majority of
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131women with PPD. PPD, then, cannot be thought of as a
simple hormonal excess or deficiency state.If there is no
reproductive endocrine abnormality in women with
PPD,and symptoms,at least in some cases,develop dur-
ing pregnancy, could PPD represent an altered sensitiv-
ity to reproductive steroids in a subgroup of women?
Supportive evidence for this role of differential sensitiv-
ity is drawn from two indirect sources.First,vulnerabili-
ty to PPD appears to associate with vulnerability to other
reproductive endocrine–related mood disorders.Several
studies,
197,198 for example,report marked elevations in the
prevalence of a history of PPD (up to 68%) in women
with PMS,and high postpartum depressive scores have
been associated with a history of PMS.
199,200 Second,the
relevance of reproductive steroids is suggested by recent
reports of the efficacy of hormonal treatments of PPD.
These reports suggest the acute
201 and prophylactic
202 anti-
depressant effects of estradiol in women with PPD,with
the recurrence rate in the latter study reduced to 9%
from an anticipated rate of 35% to 60%.
Direct evidence in support of the role of reproductive
steroids in the development of PPD comes from a study
in which a scaled-down form of pregnancy and parturi-
tion was created in euthymic women with and without a
history of PPD. Use of this model permitted examina-
tion of the role of reproductive steroids in postpartum
mood symptoms without many of the factors that con-
found efforts to study PPD, including dramatic concur-
rent changes in other endocrine axes (eg,hypothalamo-
pituitary-adrenal [HPA] axis), obstetrical pain and
complications,varying levels of social support,and stress
secondary to childbirth and motherhood. The GnRH
agonist leuprolide acetate was used to suppress ovarian
steroid production and create a stable hypogonadal
baseline, following which supraphysiologic doses of
estradiol and progesterone were administered for 2
months and then abruptly (and blindly) withdrawn.This
methodology replicated (albeit on a smaller scale) both
the elevated reproductive steroid levels seen during
pregnancy and the precipitous decline in levels at par-
turition.Five of the eight women with a history of PPD,
and none of the controls, developed significant mood
symptoms during both hormone addback and with-
drawal, findings consistent with observations that the
incidence of depressive symptoms is increased during
both the last trimester and postpartum.This study sug-
gests a direct role for estradiol or progesterone or both
in PPD and further demonstrates that women with a his-
tory of PPD are differentially sensitive to the mood-
destabilizing effects of marked changes in levels of
reproductive steroids.
Conclusions
The differential sensitivity to gonadal steroids seen in
women with histories of PMS and PPD emphasizes that
the response to a biological signal cannot be inferred
without an understanding of the context in which the
signal occurs.This context includes current physiologi-
cal and external environments,prior experience,past his-
tory of exposure to the stimulus, and genetic makeup.
With the mapping of the human genome, this last con-
textual determinant becomes of great practical interest
as a potential explanation for differential response to
steroids.
While genetic polymorphisms clearly influence the tran-
scriptional, physiological, and behavioral responses to
activated steroid receptors, it seems equally clear that
genetic factors will contribute to,but not solely provide,
the explanation for the differential sensitivity seen in
women with PMS and PPD. Indeed, even where genet-
ic strain differences are apparent in behavioral sensitiv-
ity to reproductive steroids, not all strain members
demonstrate the observed steroid-stimulated behavior.
150
Further, the observed alterations in reproductive
steroid–sensitive neurocircuitry, reproductive steroid–
activated gene expression,and adult behavior following
differential exposure to perinatal steroids
23,203,204 caution
us that gene–environment interactions may yield
markedly different phenotypic expressions of the same
genotype.The variable influences on behavior,then,are
not likely to reduce to simple, unitary explanations for
the susceptibility to depression. Nonetheless, by recog-
nizing that a biological stimulus may trigger an affective
state change (operate as an affective trigger) only in a
specific context of susceptibility,we are in a much better
position to meaningfully explore and uncover the patho-
physiology of depression. By illuminating the mecha-
nisms underlying the differential sensitivity to repro-
ductive steroids exemplified by women with PMS and
PPD,we will significantly advance our understanding of
the neurobiology of affective illness.❏
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Esteroides gonadales, cerebro y conducta:
papel del contexto
La naturaleza y extensión de la influencia del sexo
y la función reproductora en el ánimo ha sido obje-
to por siglos de especulación y controversia. En los
últimos 50 años; sin embargo, se ha demostrado
cada vez con mayor claridad que no es sólo el cere-
bro el blanco principal de las hormonas esteroida-
les de la reproducción, sino que adicionalmente, las
hormonas esteroidales – como neurorreguladores-
dan origen a un contexto que influye en una
amplia gama de actividades cerebrales. Por ejem-
plo, las acciones neurales y las conductas resultan-
tes son marcadamente diferentes en presencia o
ausencia de esteroides gonadales. A su vez, las
acciones de los esteroides gonadales son por sí
mismas dependientes del contexto. De este modo,
aun cuando se pueda demostrar que los esteroides
gonadales provocan trastornos del ánimo, esta pro-
vocación occurre con niveles hormonales normales
(en oposición a los trastornos del ánimo que acom-
pañan a las endocrinopatías) y los trastornos del
ánimo aparecen sólo en un subgrupo de individuos
sensibles. La especificidad del contexto y la dife-
rente susceptibilidad para la disregulación afectiva
que se observa en mujeres con trastornos del
ánimo relacionados con el ciclo reproductor endo-
crino, son sin lugar a dudas importantes caracterís-
ticas que subyacen a una amplia gama de trastor-
nos psiquiátricos en los que los factores gatillo aun
no han sido identificados. En consecuencia, los tras-
tornos del ánimo relacionados con el ciclo repro-
ductor endocrino ofrecen una esperanza sin igual
para la identificación de aquellas variables del con-
texto que permiten que estímulos biológicos se
transformen específicamente en depresión en indi-
viduos que están en riesgo.
Stéroïdes gonadiques, cerveau et 
comportement : rôle du contexte
La nature et l’importance de l’influence des fonc-
tions sexuelles et reproductives sur l’humeur ont
été l’objet de discussion et de controverse depuis
des siècles. Cependant, depuis les 50 dernières
années, il est devenu de plus en plus évident que
non seulement le cerveau est une cible majeure des
hormones stéroïdiennes de la reproduction, mais
qu’en plus les hormones stéroïdiennes, en tant que
neurorégulateurs, créent un contexte qui influe sur
une large gamme d’activités cérébrales, c’est-à-dire,
qu’en fonction de la présence ou de l’absence des
stéroïdes gonadiques, les effets neurologiques et
les comportements en résultant sont très différents.
De plus, les effets des hormones stéroïdiennes
gonadiques dépendent eux-mêmes du contexte.
Par conséquent, même quand il est possible de
démontrer que les hormones stéroïdiennes provo-
quent des troubles de l’humeur, ces derniers appa-
raissent pour des concentrations normales d’hor-
mones stéroïdiennes (par opposition aux troubles
de l’humeur qui accompagnent les endocrinopa-
thies), et seulement dans un sous-groupe d’indivi-
dus sensibles. La spécificité du contexte et la diffé-
rence de sensibilité individuelle aux désordres
affectifs, décrites chez des femmes ayant des
troubles de l’humeur liés aux hormones de la repro-
duction, sont de toute évidence des particularités
importantes sous-jacentes d’un large échantillon de
troubles psychiatriques pour lesquels les facteurs
déclenchants n’ont pas encore été identifiés. Par
conséquent, les troubles de l’humeur liés aux hor-
mones de la reproduction offrent une possibilité
sans précédent d’identifier les variables de ce
contexte qui permettent aux stimuli biologiques de
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